
News|Slideshows|March 31, 2022
American College of Cardiology 71st Scientific Sessions: Science Preview, April 3, 2022
Author(s)Patient Care Editorial Staff
At ACC 2022 on Sunday, 4-2, look for studies on icosapent ethyl and alirocumab, landmark research on HFrEF, and a novel anticoagulant for atrial fibrillation.
Advertisement
Late-breaking ACC science on Sunday, April 2, begins at a session jointly sponsored by the ACC and the Journal of the American Medical Association, followed by the joint ACC/New England Journal of Medicine session and a second day of featured clinical research.
Look for studies on icosapent ethyl, vupanorsen, and alirocumab for hypercholesterolemia ; for landmark research on HFrEF and on a novel FX1a inhibitor for treatment of atrial fibrillation .
Saturday, April 2, 2022 Late Breaking Clincial Trials
Monday, April 4, 2022 Late Breaking Clinical Trials
More News from ACC on Patient Care
Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Patient Care Online
1
GRAIL Submits FDA Premarket Approval Application for Galleri Multi-Cancer Early Detection Blood Test
2
Vaccine Hesitancy: Communication Strategies for Primary Care That Preserve Trust
3
Investigational Dual GLP-1/GIP Agonist CT-388 Demonstrates 22.5% Placebo-Adjusted Weight Loss in Phase 2 Obesity Trial
4


































































































































